跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 48 条关于
“ARANOTE”
全部
48
临床试验
5
药物
2
机构
4
资讯
37
2年前
NUBEQA® (darolutamide) Plus ADT Significantly Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
2年前
NUBEQA® (darolutamide) Plus ADT Significantly Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
2年前
ARANOTE Trial: Nubeqa Plus ADT Significantly Improves Outcomes in mHSPC
去年
Darolutamide Gains FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer Following ARANOTE Trial Success
2年前
ARANOTE Trial: Darolutamide Plus ADT Significantly Reduces Risk in Metastatic Hormone-Sensitive Prostate Cancer
去年
FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer Based on ARANOTE Trial Results
2年前
ARANOTE Trial: Darolutamide Plus ADT Significantly Improves Outcomes in mHSPC
去年
FDA Accepts Darolutamide sNDA for mHSPC Based on ARANOTE Trial Data
2年前
ARANOTE Trial: Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
2年前
NUBEQA Plus ADT Demonstrates 46% Risk Reduction in Metastatic Hormone-Sensitive Prostate Cancer
第 1 页,共 4 页
上一页
下一页